GSK Licenses Compendia's Oncomine for Cancer Drug Studies | GenomeWeb
NEW YORK (GenomeWeb News) – GlaxoSmithKline has licensed Compendia Bioscience’s Oncomine Enterprise Edition database for use in its cancer research programs, Compendia said today.
The pharmaceutical company has licensed the database, which is an extension of the Oncomine line, under a two-year agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.